Anti-TCR-alphabeta monoclonal antibody H57-597

Drug Profile

Anti-TCR-alphabeta monoclonal antibody H57-597

Alternative Names: Anti-alphabeta monoclonal antibody H57; Anti-T-cell-receptor-alphabeta monoclonal antibody H57-597; anti-T-cell-receptor-αβ monoclonal antibody H57-597; anti-αβ monoclonal antibody H57; H57; H57-597

Latest Information Update: 10 Aug 1998

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Unknown
  • Developer Nissui Pharmaceutical; Nonindustrial source
  • Class Monoclonal antibodies
  • Mechanism of Action T-cell receptor antigen alpha-beta antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Graft-versus-host disease; Transplant rejection

Most Recent Events

  • 10 Aug 1998 No-Development-Reported for Graft-versus-host disease in Japan (Unknown route)
  • 10 Aug 1998 No-Development-Reported for Transplant rejection in Japan (Unknown route)
  • 10 Aug 1998 No-Development-Reported for Transplant rejection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top